See the Full Picture.
Published loading...Updated

Exercise may benefit colon cancer patients as much as some drugs: Study

  • Pfizer presented new data on Braftovi, a targeted colorectal cancer drug, showing it doubled survival time in aggressive cases in 2025.
  • The drug’s effectiveness depends on identifying cancer-driving mutations, reflecting advances in personalized cancer treatments over two decades.
  • A separate study showed that colorectal patients who exercised regularly and followed anti-inflammatory diets had significantly improved survival rates.
  • This exercise program reduced risk of recurrence by 28%, with a five-year disease-free survival of 80%, compared to 74% without it, experts said.
  • These findings suggest combining targeted drugs with lifestyle changes could empower patients and potentially improve outcomes amid rising cancer cases in younger adults.
Insights by Ground AI
Does this summary seem wrong?

262 Articles

All
Left
40
Center
132
Right
17
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 70% of the sources are Center
70% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Savage Nation broke the news in on Friday, May 30, 2025.
Sources are mostly out of (0)